This report, written by the Taskforce Horizon Scanning of the Beneluxa Initiative, describes the current situation of Haemophilia and provides an overview of new pharmaceutical developments regarding this disease. The current treatment options are listed, as well as the pharmaceutical costs in some of the Beneluxa countries.
The focus of this report are the pharmaceuticals with the potential to enter the market in the upcoming years. These are displayed in a detailed table. The setup of the clinical trials, including the used biomarkers, are summarised. Also, the possible challenges, both on HTA level as on Health care level, are described.
With this report, the Beneluxa Initiative aims to timely inform policy makers, healthcare organizations, payers and the general public on upcoming new pharmaceuticals and possible challenges.
Last update: 15 June 2022